Table III.
Multivariate analysis for the association between biologics use and the composite of moderate to severe COVID-19 or all-cause mortality within 90 d following PCR date among adult asthmatic patients with positive PCR test result for SARS-CoV-2 (n = 8242)
| Variable | Adjusted∗ HR (95% CI) | P value |
|---|---|---|
| Age (for each year increase) | 1.057 (1.050-1.063) | <.001 |
| Sex | ||
| Males | 1.23 (1.03-1.48) | .023 |
| Females | Reference | |
| Ethnicity | ||
| Jews | Reference | |
| Arabs | 1.56 (1.30-1.88) | <.001 |
| Diabetes | 1.36 (1.13-1.63) | .001 |
| Hypertension | 1.35 (1.07-1.70) | .010 |
| Obesity | 1.36 (1.13-1.63) | .001 |
| IHD | 1.37 (1.13-1.67) | .001 |
| Smoking (ever) | 1.05 (0.87-1.26) | .590 |
| Steroids use in the previous year (no. of filled prescriptions) | ||
| None | Reference | |
| 1 prescription | 1.01 (0.78-1.30) | .955 |
| 2 prescriptions | 1.39 (1.00-1.93) | .049 |
| ≥3 prescriptions | 1.92 (1.52-2.41) | <.001 |
| Biologics use (at least 1 prescription filled in the previous 120 d) | ||
| None | Reference | |
| Yes | 1.42 (0.70-2.88) | .332 |
IHD, Ischemic heart disease.
∗
Adjusted for age, sex, ethnicity, diabetes, hypertension, IHD, obesity, smoking, and steroids and biologics use.